Stock Scorecard
Stock Summary for Sarepta Therapeutics Inc (SRPT) - $19.94 as of 2/5/2026 8:12:43 AM EST
Total Score
10 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SRPT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SRPT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SRPT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SRPT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SRPT (27 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for SRPT
Financial Details for SRPT
Company Overview |
|
|---|---|
| Ticker | SRPT |
| Company Name | Sarepta Therapeutics Inc |
| Country | N/A |
| Description | Sarepta Therapeutics, Inc. is a pioneering biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing RNA-targeted and gene therapies for rare genetic disorders, with a primary focus on Duchenne muscular dystrophy (DMD). With a strong and innovative pipeline, Sarepta is actively addressing significant unmet medical needs through its advanced therapeutic solutions, positioning the company as a leader in the genetic medicine arena. By leveraging cutting-edge scientific expertise and technology, Sarepta aims to redefine treatment options and improve patient outcomes in the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/25/2026 |
Stock Price History |
|
| Last Day Price | 19.94 |
| Price 4 Years Ago | 129.58 |
| Last Day Price Updated | 2/5/2026 8:12:43 AM EST |
| Last Day Volume | 2,393,270 |
| Average Daily Volume | 2,799,776 |
| 52-Week High | 120.05 |
| 52-Week Low | 10.41 |
| Last Price to 52 Week Low | 91.55% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.21 |
| Sector PE | 34.82 |
| 5-Year Average PE | -3.11 |
| Free Cash Flow Ratio | 3.41 |
| Industry Free Cash Flow Ratio | 12.52 |
| Sector Free Cash Flow Ratio | 33.33 |
| Current Ratio Most Recent Quarter | 2.95 |
| Total Cash Per Share | 5.85 |
| Book Value Per Share Most Recent Quarter | 12.60 |
| Price to Book Ratio | 1.69 |
| Industry Price to Book Ratio | 53.70 |
| Sector Price to Book Ratio | 53.77 |
| Price to Sales Ratio Twelve Trailing Months | 0.92 |
| Industry Price to Sales Ratio Twelve Trailing Months | 21.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.66 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 104,787,000 |
| Market Capitalization | 2,089,452,780 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.26% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 2,664.00% |
| Annual Earnings Growth | 143.89% |
| Reported EPS 12 Trailing Months | -2.83 |
| Reported EPS Past Year | -1.53 |
| Reported EPS Prior Year | 2.68 |
| Net Income Twelve Trailing Months | -271,514,000 |
| Net Income Past Year | 235,239,000 |
| Net Income Prior Year | -535,977,000 |
| Quarterly Revenue Growth YOY | -14.50% |
| 5-Year Revenue Growth | 37.94% |
| Operating Margin Twelve Trailing Months | -15.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 613,077,000 |
| Total Cash Past Year | 1,103,010,000 |
| Total Cash Prior Year | 428,430,000 |
| Net Cash Position Most Recent Quarter | -422,069,000 |
| Net Cash Position Past Year | -34,114,000 |
| Long Term Debt Past Year | 1,137,124,000 |
| Long Term Debt Prior Year | 1,132,515,000 |
| Total Debt Most Recent Quarter | 1,035,146,000 |
| Equity to Debt Ratio Past Year | 0.57 |
| Equity to Debt Ratio Most Recent Quarter | 0.56 |
| Total Stockholder Equity Past Year | 1,527,742,000 |
| Total Stockholder Equity Prior Year | 859,337,000 |
| Total Stockholder Equity Most Recent Quarter | 1,320,120,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -388,840,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.71 |
| Free Cash Flow Past Year | -352,743,000 |
| Free Cash Flow Prior Year | -588,338,000 |
Options |
|
| Put/Call Ratio | 0.53 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.22 |
| MACD Signal | -0.01 |
| 20-Day Bollinger Lower Band | 17.49 |
| 20-Day Bollinger Middle Band | 21.12 |
| 20-Day Bollinger Upper Band | 24.74 |
| Beta | 0.48 |
| RSI | 43.44 |
| 50-Day SMA | 33.99 |
| 150-Day SMA | 92.37 |
| 200-Day SMA | 95.36 |
System |
|
| Modified | 2/5/2026 4:23:03 AM EST |